6501-72-0 | (3-Phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$14.00	$10.00
10mg	98%	in stock	$47.00	$33.00
25mg	98%	in stock	$67.00	$47.00
50mg	98%	in stock	$94.00	$66.00
100mg	98%	in stock	$150.00	$105.00

Description

• Catalog Number: AG69073
• Chemical Name: (3-Phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid
• CAS Number: 6501-72-0
• Molecular Formula: C11H11NO3
• Molecular Weight: 205.2099
• MDL Number: MFCD08696167
• SMILES: OC(=O)CC1ON=C(C1)c1ccccc1

Computed Properties

• Complexity: 269
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 15
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 3
• Undefined Atom Stereocenter Count: 1
• XLogP3: 1.3

Literature

• Therapeutic potential of nitric oxide-modified drugs in colon cancer cells.

  Molecular pharmacology 20121001

• Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO.

  Free radical biology & medicine 20100415

• The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis.

  European journal of pharmacology 20090801

• Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats.

  British journal of pharmacology 20081101

• Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells.

  Nitric oxide : biology and chemistry 20080901

• In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027.

  European journal of pharmacology 20080531

• Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo.

  Molecular cancer therapeutics 20080301

• In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models.

  Clinical immunology (Orlando, Fla.) 20070601

• A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice.

  The Journal of pharmacology and experimental therapeutics 20070301

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419